| 000 | 01102 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250515152017.0 | ||
| 264 | 0 | _c20090116 | |
| 008 | 200901s 0 0 eng d | ||
| 022 | _a1871-5303 | ||
| 024 | 7 |
_a10.2174/187153008786848268 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMontecucco, Fabrizio | |
| 245 | 0 | 0 |
_aDoes non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? _h[electronic resource] |
| 260 |
_bEndocrine, metabolic & immune disorders drug targets _cDec 2008 |
||
| 300 |
_a301-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xcomplications |
| 650 | 0 | 4 |
_aFatty Liver _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 |
_aMetabolic Syndrome _xphysiopathology |
| 650 | 0 | 4 | _aRisk |
| 700 | 1 | _aMach, Francois | |
| 773 | 0 |
_tEndocrine, metabolic & immune disorders drug targets _gvol. 8 _gno. 4 _gp. 301-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/187153008786848268 _zAvailable from publisher's website |
| 999 |
_c18528490 _d18528490 |
||